DYANAVEL XR and Perigon Logo

Welcome to
DYANAVEL Delivered!

Your healthcare provider has prescribed your medication through DYANAVEL Delivered, a program to help you easily get DYANAVEL® XR (amphetamine) tablets.

What’s next?

Once your prescription has been submitted, you will receive a call from Perigon Pharmacy 360 within one business day to confirm your information. Be sure to answer this call.

What can you expect?

Truck icon

GUARANTEED AVAILABILITY

Perigon Pharmacy 360 works directly with Tris Pharma to ensure DYANAVEL XR tablets are always available.

Bell icon

FULL PATIENT SUPPORT

If you have any questions or concerns, call 1.844.698.2533. The Care Delivery team is available to help you from 9 AM to 6 PM ET, Monday-Friday.

Dollar icon

FREE & FAST DELIVERY

DYANAVEL XR tablets will be delivered directly to the address of your choice with no delivery fee (signature required).

Note: Not available for delivery to all areas. Program not for patients in California, Washington DC and Puerto Rico.

What will you pay?

$25 per month with copay savings program* if your commercial insurance covers DYANAVEL XR tablets

$100 per month for all eligible patients who choose to pay cash*

* Restrictions apply, please see details below.

Questions? We also deliver answers.

Perigon Pharmacy 360 will have a Care Delivery team available to answer questions about the DYANAVEL Delivered program on weekdays from 9 AM-6 PM ET.

phone icon 1.844.698.2533

Click Here For more information on DYANAVEL XR tablets

All offer amounts are for a maximum of a 30-day supply of product.

*RESTRICTIONS:

All DYANAVEL XR tablet savings offers are valid only in the United States and Puerto Rico. By using these offers, the patient certifies that he or she will comply with any terms of his or her health insurance contract requiring notification to his or her payer of the existence and/or value of the offers. It is illegal to (or offer to) sell, purchase, or trade these offers. These offers are not transferable and is limited to one offer per person per prescription. Void where prohibited by law. Tris Pharma reserves the right to rescind, revoke, or amend these offers without notice at any time.

Patients with government insurance includes all patients who are a member, recipient or beneficiary of a government healthcare program such as Medicaid, a Medicare drug benefit plan, TRICARE, or other federal or state health programs (such as medical assistance programs).

Copay Savings Program: This offer is for patients with commercial or private insurance only and not for patients with government insurance. Copay for high deductible plans may vary. Cash Discount Cards and other non-insurance plans are not valid as primary under this offer. If the patient is eligible for drug benefits under any such program, the patient cannot use this offer.

Cash Offer: This offer is available to patients if they have no insurance or are underinsured such that the patient’s applicable insurance does not adequately cover the cost of DYANAVEL. Only valid through the DYANAVEL Delivered by Perigon program.

Not for patients with prescription insurance through State Medicaid or Managed Medicaid plans. For patients with other government insurance, the patient must agree in writing to not submit a claim for reimbursement to any government insurance program and commit to paying the cash price though the end of the defined plan year. Patients may not count the cash price paid via the Cash Offer as an expense incurred for purposes of determining out-of-pocket costs for any government insurance plan, including true out-of-pocket costs (TrOOP), for purposes of calculating the out-of-pocket spending threshold or triggering catastrophic coverage for Medicare Part D plans.

Quick Start Offer: This offer is available to patients who are new to DYANAVEL tablet therapy, have a valid prescription, have commercial or government insurance that does not exclude participation in the program, and have an ongoing (>24 hours) coverage-decision delay after submission of a completed prior authorization or other similar reimbursement request. This offer is limited to one use per patient per lifetime and is non-transferable. By redeeming this offer, patient certifies that they have not previously filled a prescription for DYANAVEL tablet. The Quick Start Program for the specified prescription cannot be combined with any other rebate/coupon, free trial, or similar offer. No substitutions are permitted. Patient is responsible for applicable taxes, if any. Only valid through the DYANAVEL Delivered by Perigon program.

Patients cannot seek reimbursement for DYANAVEL supplied to the patient via the Quick Start Program from health insurance or any third party, including state or federally funded programs. Patients may not count the DYANAVEL supplied to the patient via the Quick Start Program as an expense incurred for purposes of determining out-of-pocket costs for any government insurance plan, including true out-of-pocket costs (TrOOP), for purposes of calculating the out-of-pocket threshold or triggering catastrophic coverage for Medicare Part D plans.

Please see Full Prescribing Information, including Boxed Warning regarding Abuse, Misuse and Addiction.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare professional. All decisions regarding patient care must be made with a healthcare professional, considering the unique characteristics of the patient.

This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our online privacy policy for more information. While Tris Pharma makes reasonable efforts to include accurate, up-to-date information on the site, Tris Pharma makes no warranties or representations as to its accuracy. Tris Pharma assumes no liability for any errors or omissions in the content of the site.

DYANAVEL XR Trablet logo Tris Pharma logo

DYANAVEL is a registered trademark of Tris Pharma, Inc. © 2023 Tris Pharma, Inc. All rights reserved.
DXR.2090.PR 10/23